{
    "chemotherapy": {
        "title": "Common Chemotherapy Drugs",
        "description": "Core cytotoxic agents used in leukemia and cancer regimens.",
        "drugs": [
            {
                "name": "6-Mercaptopurine",
                "classification": "Antimetabolite",
                "route": "Oral",
                "extravasationRisk": "Non-vesicant",
                "mechanism": [
                    "Purine analog that interferes with DNA and RNA synthesis."
                ],
                "indications": [
                    "ALL maintenance",
                    "Mercaptopurine-based regimens"
                ],
                "sideEffects": [
                    "Myelosuppression",
                    "Hepatotoxicity",
                    "GI upset"
                ],
                "monitoring": [
                    "CBC",
                    "LFTs",
                    "TPMT enzyme activity"
                ],
                "warnings": [
                    "Avoid with allopurinol unless dose-adjusted",
                    "Dose adjust in hepatic impairment"
                ],
                "nursingInfo": [
                    "Give on an empty stomach.",
                    "Avoid milk within 1–2 hours.",
                    "Monitor jaundice or abdominal pain."
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Bleomycin",
                "classification": "Antitumor Antibiotic",
                "route": "IV, IM, Subcutaneous",
                "extravasationRisk": "Irritant",
                "mechanism": [
                    "Induces DNA strand breaks through free-radical formation."
                ],
                "indications": [
                    "Hodgkin lymphoma",
                    "Testicular cancer"
                ],
                "sideEffects": [
                    "Pulmonary toxicity",
                    "Fever",
                    "Skin changes"
                ],
                "monitoring": [
                    "Baseline & periodic PFTs",
                    "Chest symptoms",
                    "Skin assessment"
                ],
                "warnings": [
                    "High oxygen concentrations increase lung toxicity"
                ],
                "nursingInfo": [
                    "Premedicate if fever-prone",
                    "Report cough or dyspnea immediately"
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Busulfan",
                "classification": "Alkylating Agent",
                "route": "Oral or IV infusion",
                "extravasationRisk": "Non-vesicant",
                "mechanism": [
                    "Alkylates DNA causing cross-linking and apoptosis."
                ],
                "indications": [
                    "AML conditioning regimen",
                    "CML (historical use)"
                ],
                "sideEffects": [
                    "Pulmonary fibrosis",
                    "Seizures",
                    "Myelosuppression"
                ],
                "monitoring": [
                    "CBC",
                    "Pulmonary exams",
                    "Busulfan levels if ordered"
                ],
                "warnings": [
                    "May require seizure prophylaxis at high doses"
                ],
                "nursingInfo": [
                    "Monitor lung symptoms",
                    "Ensure anticonvulsant prophylaxis when ordered"
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Cisplatin",
                "classification": "Platinum Compound",
                "route": "IV infusion",
                "extravasationRisk": "Vesicant",
                "mechanism": [
                    "Causes DNA cross-linking and apoptosis."
                ],
                "indications": [
                    "Solid tumors",
                    "Lymphomas (selected protocols)"
                ],
                "sideEffects": [
                    "Nephrotoxicity",
                    "Ototoxicity",
                    "Nausea/vomiting"
                ],
                "monitoring": [
                    "Renal function",
                    "Electrolytes (Mg, K)",
                    "Hearing tests"
                ],
                "warnings": [
                    "Requires vigorous hydration",
                    "High emetogenic risk"
                ],
                "nursingInfo": [
                    "Check urine output",
                    "Ensure pre- and post-hydration",
                    "Monitor for tinnitus"
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Cyclophosphamide",
                "classification": "Alkylating Agent",
                "route": "IV infusion",
                "extravasationRisk": "Non-vesicant",
                "mechanism": [
                    "Alkylates DNA leading to cell death."
                ],
                "indications": [
                    "ALL",
                    "Lymphomas",
                    "HyperCVAD A"
                ],
                "sideEffects": [
                    "Hemorrhagic cystitis",
                    "Myelosuppression",
                    "Alopecia"
                ],
                "monitoring": [
                    "Urine output",
                    "CBC",
                    "Signs of cystitis"
                ],
                "warnings": [
                    "Use mesna if high dose",
                    "Ensure hydration"
                ],
                "nursingInfo": [
                    "Hydrate before/after dose",
                    "Monitor for hematuria"
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Cytarabine (Ara-C)",
                "classification": "Antimetabolite",
                "route": "IV infusion or Subcutaneous",
                "extravasationRisk": "Irritant",
                "mechanism": [
                    "Pyrimidine analog inhibiting DNA polymerase."
                ],
                "indications": [
                    "AML induction/consolidation",
                    "ALL protocols"
                ],
                "sideEffects": [
                    "Neurotoxicity",
                    "Conjunctivitis",
                    "Myelosuppression"
                ],
                "monitoring": [
                    "Neuro checks",
                    "Eye symptoms",
                    "CBC"
                ],
                "warnings": [
                    "High-risk for cerebellar toxicity in elderly or renal impairment"
                ],
                "nursingInfo": [
                    "Use steroid eye drops",
                    "Perform neuro exam before each high dose"
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Daunorubicin",
                "classification": "Anthracycline",
                "route": "IV push (central line)",
                "extravasationRisk": "Vesicant",
                "mechanism": [
                    "Intercalates DNA and inhibits topoisomerase II."
                ],
                "indications": [
                    "AML",
                    "ALL",
                    "3+7 regimen"
                ],
                "sideEffects": [
                    "Cardiotoxicity",
                    "Red urine",
                    "Myelosuppression"
                ],
                "monitoring": [
                    "Ejection fraction",
                    "ECG",
                    "CBC"
                ],
                "warnings": [
                    "Strict vesicant precautions"
                ],
                "nursingInfo": [
                    "Use central line only",
                    "Expect red urine for 24–48 hrs"
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Doxorubicin",
                "classification": "Anthracycline",
                "route": "IV push (central line)",
                "extravasationRisk": "Vesicant",
                "mechanism": [
                    "Intercalates DNA and produces free radicals."
                ],
                "indications": [
                    "Lymphomas",
                    "ALL",
                    "Solid tumors"
                ],
                "sideEffects": [
                    "Cardiotoxicity",
                    "Red urine",
                    "Myelosuppression"
                ],
                "monitoring": [
                    "Ejection fraction",
                    "ECG",
                    "CBC"
                ],
                "warnings": [
                    "Lifetime max dose limit",
                    "Avoid extravasation"
                ],
                "nursingInfo": [
                    "Give via dedicated central line",
                    "Observe for chest discomfort"
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Etoposide",
                "classification": "Topoisomerase II Inhibitor",
                "route": "IV infusion or Oral",
                "extravasationRisk": "Irritant",
                "mechanism": [
                    "Blocks topoisomerase II causing DNA breaks."
                ],
                "indications": [
                    "Lymphomas",
                    "AML protocols"
                ],
                "sideEffects": [
                    "Hypotension",
                    "Myelosuppression"
                ],
                "monitoring": [
                    "CBC",
                    "Blood pressure during infusion"
                ],
                "warnings": [
                    "Avoid rapid IV push"
                ],
                "nursingInfo": [
                    "Use infusion pump",
                    "Monitor BP throughout infusion"
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Ifosfamide",
                "classification": "Alkylating Agent",
                "route": "IV infusion",
                "extravasationRisk": "Non-vesicant",
                "mechanism": [
                    "DNA alkylation and cross-linking."
                ],
                "indications": [
                    "Lymphomas",
                    "Solid tumors"
                ],
                "sideEffects": [
                    "Hemorrhagic cystitis",
                    "CNS toxicity",
                    "Myelosuppression"
                ],
                "monitoring": [
                    "Mental status",
                    "Urine output",
                    "CBC"
                ],
                "warnings": [
                    "Always requires mesna"
                ],
                "nursingInfo": [
                    "Ensure hydration",
                    "Observe for confusion or hallucinations"
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Methotrexate",
                "classification": "Antimetabolite",
                "route": "IV, Oral, Intrathecal",
                "extravasationRisk": "Non-vesicant",
                "mechanism": [
                    "Inhibits dihydrofolate reductase, blocking DNA synthesis."
                ],
                "indications": [
                    "ALL",
                    "Lymphomas",
                    "CNS prophylaxis"
                ],
                "sideEffects": [
                    "Mucositis",
                    "Renal toxicity"
                ],
                "monitoring": [
                    "Renal function",
                    "MTX levels",
                    "CBC"
                ],
                "warnings": [
                    "Avoid NSAIDs & cotrimoxazole"
                ],
                "nursingInfo": [
                    "Give leucovorin rescue for high-dose MTX"
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Vincristine",
                "classification": "Vinca Alkaloid",
                "route": "IV push (NEVER intrathecal)",
                "extravasationRisk": "Vesicant",
                "mechanism": [
                    "Inhibits microtubule formation."
                ],
                "indications": [
                    "ALL",
                    "Lymphomas",
                    "Myeloma regimens"
                ],
                "sideEffects": [
                    "Peripheral neuropathy",
                    "Constipation"
                ],
                "monitoring": [
                    "Bowel pattern",
                    "Neuropathy symptoms"
                ],
                "warnings": [
                    "Fatal if given intrathecally"
                ],
                "nursingInfo": [
                    "Check for foot drop",
                    "Avoid compressing infusion limb"
                ],
                "source": "Local Hospital Formulary"
            }
        ]
    },
    "targetedTherapy": {
        "title": "Common Targeted and Monoclonal Therapies",
        "description": "Biologic and molecular agents used in leukemia, lymphoma, and solid tumors.",
        "drugs": [
            {
                "name": "Atezolizumab",
                "classification": "PD-L1 Inhibitor (Immunotherapy)",
                "route": "IV infusion",
                "extravasationRisk": "Non-vesicant",
                "mechanism": [
                    "Blocks PD-L1 interaction to enhance T-cell immune response."
                ],
                "indications": [
                    "Lung cancer",
                    "Urothelial cancer",
                    "Immunotherapy combinations"
                ],
                "sideEffects": [
                    "Fatigue",
                    "Colitis",
                    "Dermatitis",
                    "Hepatitis"
                ],
                "monitoring": [
                    "LFTs",
                    "Thyroid function",
                    "Immune-related symptoms"
                ],
                "warnings": [
                    "Hold treatment for grade 3/4 immune toxicities"
                ],
                "nursingInfo": [
                    "Assess for diarrhea, abdominal pain (colitis).",
                    "Monitor liver enzymes closely.",
                    "Educate patient about delayed immune side effects."
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Bevacizumab",
                "classification": "VEGF Inhibitor (Monoclonal Antibody)",
                "route": "IV infusion",
                "extravasationRisk": "Non-vesicant",
                "mechanism": [
                    "Inhibits VEGF, preventing tumor angiogenesis."
                ],
                "indications": [
                    "Colon cancer",
                    "Ovarian cancer",
                    "Glioblastoma"
                ],
                "sideEffects": [
                    "Hypertension",
                    "Proteinuria",
                    "Delayed wound healing"
                ],
                "monitoring": [
                    "BP",
                    "Urine protein",
                    "Signs of bleeding"
                ],
                "warnings": [
                    "Avoid during active bleeding or recent surgery"
                ],
                "nursingInfo": [
                    "Check BP before each cycle.",
                    "Dipstick urine for proteinuria.",
                    "Delay dose if uncontrolled hypertension."
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Bortezomib",
                "classification": "Proteasome Inhibitor",
                "route": "IV or Subcutaneous",
                "extravasationRisk": "Irritant",
                "mechanism": [
                    "Blocks proteasome activity leading to apoptosis."
                ],
                "indications": [
                    "Multiple myeloma",
                    "Mantle cell lymphoma"
                ],
                "sideEffects": [
                    "Peripheral neuropathy",
                    "Thrombocytopenia",
                    "Diarrhea"
                ],
                "monitoring": [
                    "CBC",
                    "Neuropathy signs"
                ],
                "warnings": [
                    "Avoid intrathecal administration"
                ],
                "nursingInfo": [
                    "Rotate SC sites after each dose.",
                    "Assess for numbness or tingling.",
                    "Administer antiviral prophylaxis (shingles)."
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Cetuximab",
                "classification": "EGFR Inhibitor (Monoclonal Antibody)",
                "route": "IV infusion",
                "extravasationRisk": "Irritant",
                "mechanism": [
                    "Targets EGFR to inhibit tumor proliferation."
                ],
                "indications": [
                    "Colorectal cancer",
                    "Head & neck cancers"
                ],
                "sideEffects": [
                    "Acneiform rash",
                    "Infusion reactions",
                    "Hypomagnesemia"
                ],
                "monitoring": [
                    "Electrolytes (Mg)",
                    "Skin changes",
                    "Respiratory status during infusion"
                ],
                "warnings": [
                    "Premedicate before each infusion"
                ],
                "nursingInfo": [
                    "Skin rash may indicate response—educate patient.",
                    "Use sunscreen; photosensitivity risk.",
                    "Monitor electrolytes weekly."
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Imatinib",
                "classification": "Tyrosine Kinase Inhibitor (TKI)",
                "route": "Oral",
                "extravasationRisk": "Non-vesicant",
                "mechanism": [
                    "Inhibits BCR-ABL tyrosine kinase."
                ],
                "indications": [
                    "CML (first-line)",
                    "Ph+ ALL"
                ],
                "sideEffects": [
                    "Edema",
                    "Muscle cramps",
                    "Nausea"
                ],
                "monitoring": [
                    "CBC",
                    "LFTs",
                    "Fluid retention"
                ],
                "warnings": [
                    "Take with food to reduce GI upset"
                ],
                "nursingInfo": [
                    "Assess for ankle/eyelid swelling.",
                    "Take with a full glass of water and meal.",
                    "Monitor LFTs regularly."
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Nivolumab",
                "classification": "PD-1 Inhibitor (Immunotherapy)",
                "route": "IV infusion",
                "extravasationRisk": "Non-vesicant",
                "mechanism": [
                    "Blocks PD-1 pathway to restore immune activation."
                ],
                "indications": [
                    "Lymphoma",
                    "Lung cancer",
                    "Melanoma"
                ],
                "sideEffects": [
                    "Immune hepatitis",
                    "Pneumonitis",
                    "Colitis"
                ],
                "monitoring": [
                    "LFTs",
                    "TSH",
                    "Respiratory symptoms"
                ],
                "warnings": [
                    "Interrupt therapy for severe immune toxicity"
                ],
                "nursingInfo": [
                    "Screen for cough/dyspnea.",
                    "Assess bowel habit changes.",
                    "Educate about delayed immune effects."
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Pembrolizumab",
                "classification": "PD-1 Inhibitor (Immunotherapy)",
                "route": "IV infusion",
                "extravasationRisk": "Non-vesicant",
                "mechanism": [
                    "Enhances anti-tumor immunity by blocking PD-1."
                ],
                "indications": [
                    "Lung cancer",
                    "Melanoma",
                    "Lymphoma"
                ],
                "sideEffects": [
                    "Immune pneumonitis",
                    "Colitis",
                    "Thyroid dysfunction"
                ],
                "monitoring": [
                    "TSH",
                    "LFTs",
                    "Respiratory status"
                ],
                "warnings": [
                    "Stop therapy if life-threatening immune reaction occurs"
                ],
                "nursingInfo": [
                    "Observe 30–60 min post-infusion.",
                    "Report diarrhea >3 episodes/day.",
                    "Check thyroid panel every 4–6 weeks."
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Rituximab",
                "classification": "CD20 Monoclonal Antibody",
                "route": "IV infusion",
                "extravasationRisk": "Non-vesicant",
                "mechanism": [
                    "Targets CD20 on B-cells leading to depletion."
                ],
                "indications": [
                    "CLL",
                    "NHL",
                    "Autoimmune disorders"
                ],
                "sideEffects": [
                    "Infusion reactions",
                    "Tumor lysis",
                    "Infections"
                ],
                "monitoring": [
                    "Vital signs during infusion",
                    "CBC",
                    "TLS labs"
                ],
                "warnings": [
                    "Severe infusion reactions common during first dose"
                ],
                "nursingInfo": [
                    "Premedicate with antihistamine + acetaminophen.",
                    "Start infusion at slowest rate.",
                    "Have emergency medications ready."
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Sorafenib",
                "classification": "Multikinase Inhibitor",
                "route": "Oral",
                "extravasationRisk": "Non-vesicant",
                "mechanism": [
                    "Inhibits tumor cell proliferation and angiogenesis."
                ],
                "indications": [
                    "Renal cell cancer",
                    "Liver cancer",
                    "Thyroid cancer"
                ],
                "sideEffects": [
                    "Hand-foot syndrome",
                    "Diarrhea",
                    "Hypertension"
                ],
                "monitoring": [
                    "BP",
                    "Skin integrity",
                    "Electrolytes"
                ],
                "warnings": [
                    "Take on empty stomach"
                ],
                "nursingInfo": [
                    "Monitor for palm/sole redness or peeling.",
                    "Apply urea cream prophylactically.",
                    "Check BP before each cycle."
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Trastuzumab",
                "classification": "HER2 Monoclonal Antibody",
                "route": "IV infusion",
                "extravasationRisk": "Non-vesicant",
                "mechanism": [
                    "Targets HER2 receptor reducing tumor cell growth."
                ],
                "indications": [
                    "HER2-positive breast cancer",
                    "Gastric cancer"
                ],
                "sideEffects": [
                    "Cardiotoxicity",
                    "Infusion reactions"
                ],
                "monitoring": [
                    "LVEF (Echo)",
                    "ECG",
                    "Vital signs"
                ],
                "warnings": [
                    "Do NOT give with anthracyclines"
                ],
                "nursingInfo": [
                    "Check EF before starting and every 3 months.",
                    "Observe closely during first infusion.",
                    "Stop infusion if chest pain or dyspnea occurs."
                ],
                "source": "Local Hospital Formulary"
            }
        ]
    },
    "supportiveTherapy": {
        "title": "Adjuvant / Supportive Medications",
        "description": "Medications used to prevent or manage chemotherapy-related side effects and complications.",
        "drugs": [
            {
                "name": "Allopurinol",
                "classification": "Xanthine Oxidase Inhibitor",
                "route": "Oral",
                "extravasationRisk": "Non-vesicant",
                "mechanism": [
                    "Reduces uric acid formation by inhibiting xanthine oxidase."
                ],
                "indications": [
                    "Tumor lysis syndrome prevention"
                ],
                "sideEffects": [
                    "Rash",
                    "Nausea",
                    "Elevated LFTs"
                ],
                "monitoring": [
                    "Uric acid levels",
                    "Renal function"
                ],
                "warnings": [
                    "Use cautiously in renal impairment"
                ],
                "nursingInfo": [
                    "Start before induction chemo if TLS risk is high.",
                    "Encourage adequate hydration.",
                    "Teach patient to report rash immediately."
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Aprepitant / Fosaprepitant",
                "classification": "NK1 Receptor Antagonist",
                "route": "Oral (Aprepitant) or IV (Fosaprepitant)",
                "extravasationRisk": "Non-vesicant",
                "mechanism": [
                    "Blocks NK1 receptors to prevent delayed nausea and vomiting."
                ],
                "indications": [
                    "Highly emetogenic chemotherapy"
                ],
                "sideEffects": [
                    "Fatigue",
                    "Hiccups",
                    "Constipation"
                ],
                "monitoring": [
                    "Drug interactions (CYP3A4)",
                    "Nausea control"
                ],
                "warnings": [
                    "May reduce hormonal contraceptive efficacy"
                ],
                "nursingInfo": [
                    "Give with 5-HT3 antagonist + steroid.",
                    "Monitor for hiccups and fatigue.",
                    "Advise backup contraception during therapy."
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Dexamethasone",
                "classification": "Corticosteroid",
                "route": "IV or Oral",
                "extravasationRisk": "Non-vesicant",
                "mechanism": [
                    "Reduces inflammation and prevents chemotherapy-induced nausea."
                ],
                "indications": [
                    "Nausea prophylaxis",
                    "Part of chemotherapy regimens"
                ],
                "sideEffects": [
                    "Hyperglycemia",
                    "Insomnia",
                    "Mood changes"
                ],
                "monitoring": [
                    "Blood glucose",
                    "Signs of infection"
                ],
                "warnings": [
                    "Use cautiously in diabetics"
                ],
                "nursingInfo": [
                    "Best given in the morning to avoid insomnia.",
                    "Monitor blood sugars closely.",
                    "Avoid abrupt stopping after prolonged use."
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Filgrastim (G-CSF)",
                "classification": "Hematopoietic Growth Factor",
                "route": "Subcutaneous",
                "extravasationRisk": "Non-vesicant",
                "mechanism": [
                    "Stimulates neutrophil production and reduces neutropenia duration."
                ],
                "indications": [
                    "Neutropenia prevention or treatment"
                ],
                "sideEffects": [
                    "Bone pain",
                    "Headache"
                ],
                "monitoring": [
                    "CBC / ANC"
                ],
                "warnings": [
                    "Avoid giving 24 hrs before or after chemo"
                ],
                "nursingInfo": [
                    "Stop when ANC > 1000 for 2 days.",
                    "Clarify timing based on chemo day.",
                    "Use warm compresses or loratadine for bone pain."
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Furosemide",
                "classification": "Loop Diuretic",
                "route": "IV or Oral",
                "extravasationRisk": "Non-vesicant",
                "mechanism": [
                    "Increases renal excretion of sodium and water."
                ],
                "indications": [
                    "Hydration protocols",
                    "Cisplatin nephroprotection"
                ],
                "sideEffects": [
                    "Hypokalemia",
                    "Dehydration",
                    "Hypotension"
                ],
                "monitoring": [
                    "Electrolytes",
                    "Urine output",
                    "Daily weight"
                ],
                "warnings": [
                    "Avoid in severe dehydration"
                ],
                "nursingInfo": [
                    "Check potassium before giving.",
                    "Monitor urine output closely.",
                    "Record strict input/output balance."
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Leucovorin (Calcium Folinate)",
                "classification": "Folinic Acid Rescue",
                "route": "IV or Oral",
                "extravasationRisk": "Non-vesicant",
                "mechanism": [
                    "Provides reduced folate to protect cells from methotrexate toxicity."
                ],
                "indications": [
                    "High-dose methotrexate rescue"
                ],
                "sideEffects": [
                    "Nausea",
                    "Flushing"
                ],
                "monitoring": [
                    "Methotrexate levels",
                    "Renal function"
                ],
                "warnings": [
                    "Do not confuse with folic acid"
                ],
                "nursingInfo": [
                    "Administer EXACTLY on schedule.",
                    "Adjust rescue based on MTX levels.",
                    "Monitor urine pH during high-dose MTX."
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Mesna",
                "classification": "Uroprotectant",
                "route": "IV or Oral",
                "extravasationRisk": "Non-vesicant",
                "mechanism": [
                    "Binds acrolein to prevent hemorrhagic cystitis."
                ],
                "indications": [
                    "Ifosfamide",
                    "High-dose cyclophosphamide"
                ],
                "sideEffects": [
                    "Nausea",
                    "Fatigue",
                    "Bad taste"
                ],
                "monitoring": [
                    "Urine output",
                    "Hematuria"
                ],
                "warnings": [
                    "Ensure hydration to reduce bladder irritation"
                ],
                "nursingInfo": [
                    "Give EXACTLY on the hydration/chemo schedule.",
                    "Encourage drinking plenty of water.",
                    "Monitor urine color each shift."
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Ondansetron",
                "classification": "5-HT3 Antagonist",
                "route": "IV or Oral",
                "extravasationRisk": "Non-vesicant",
                "mechanism": [
                    "Blocks serotonin receptors to reduce nausea."
                ],
                "indications": [
                    "Chemotherapy-induced nausea"
                ],
                "sideEffects": [
                    "Headache",
                    "Constipation",
                    "QT prolongation"
                ],
                "monitoring": [
                    "ECG if cardiac history",
                    "Bowel movements"
                ],
                "warnings": [
                    "Use cautiously with QT-prolonging drugs"
                ],
                "nursingInfo": [
                    "Give 30 minutes before chemo.",
                    "Increase fluids/fiber for constipation.",
                    "Consider ECG in high-risk patients."
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Palonosetron",
                "classification": "5-HT3 Antagonist",
                "route": "IV infusion",
                "extravasationRisk": "Non-vesicant",
                "mechanism": [
                    "Long-acting serotonin blockade for delayed nausea control."
                ],
                "indications": [
                    "Moderate/high emetogenic chemo"
                ],
                "sideEffects": [
                    "Constipation",
                    "Headache"
                ],
                "monitoring": [
                    "Pain at IV site",
                    "Bowel habits"
                ],
                "warnings": [
                    "Used once per cycle"
                ],
                "nursingInfo": [
                    "Preferred for delayed nausea.",
                    "Give before chemotherapy begins.",
                    "Increase fiber to prevent constipation."
                ],
                "source": "Local Hospital Formulary"
            },
            {
                "name": "Pegfilgrastim",
                "classification": "Long-acting G-CSF",
                "route": "Subcutaneous",
                "extravasationRisk": "Non-vesicant",
                "mechanism": [
                    "Long-acting stimulation of neutrophil production."
                ],
                "indications": [
                    "Neutropenia prevention"
                ],
                "sideEffects": [
                    "Bone pain",
                    "Injection site pain"
                ],
                "monitoring": [
                    "CBC",
                    "Symptoms of splenic enlargement"
                ],
                "warnings": [
                    "Do NOT give within 14 days before next chemo cycle"
                ],
                "nursingInfo": [
                    "Administer 24 hours after chemotherapy.",
                    "Educate about left-upper-quadrant pain (rare splenic issue).",
                    "Use loratadine for bone pain if needed."
                ],
                "source": "Local Hospital Formulary"
            }
        ]
    }
}